Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects

被引:1
|
作者
Wang, Meng [1 ]
Zhou, Wenjia [1 ]
Zhang, Quanying [1 ]
Zong, Shunlin [1 ]
Lv, Chengzhe [2 ]
机构
[1] Soochow Univ, Clin Pharmacol Lab, Affiliated Hosp 2, Suzhou City, Jiangsu, Peoples R China
[2] Soochow Univ, Dept Pharmaceut, Childrens Hosp, Suzhou City, Jiangsu, Peoples R China
来源
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2020年 / 9卷 / 05期
关键词
rasagiline transdermal patch; pharmacokinetics; pharmacodynamics; safety; single dose; multiple dose; PARKINSON-DISEASE; MAO-B; INHIBITOR; PATHOGENESIS;
D O I
10.1002/cpdd.761
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A rasagiline transdermal patch can be used to offer continuous rasagiline to patients with Parkinson's disease who cannot take their usual oral medications. This was the first study to investigate the pharmacokinetics, pharmacodynamics, and safety of the rasagiline transdermal patch in healthy Chinese subjects. Thirty subjects were randomized to 3 groups with 10 subjects in each group. The 10 subjects of group 1 received a single 1-mg dose of rasagiline as a tablet; the 20 subjects of groups 2 and 3 received a single transdermal patch (48-hour patch-on period) containing 1.25 mg and 2.5 mg rasagiline, respectively. After a 2-week washout period, the subjects of group 1 were assigned to receive 1 mg of rasagiline tablets every 24 hours for 7 days, and the subjects of group 2 were assigned to receive 1.25-mg rasagiline transdermal patches (48-hour patch-on period) every 72 hours for 5 time periods. The absorption of rasagiline from the transdermal patch was significantly improved, although the peak plasma concentration was obviously reduced. There was slight accumulation of rasagiline dose after multiple administrations. Inhibition of platelet monoamine oxidase-B (MAO-B) activity was dose dependent. The 80% inhibition maintained for at least 48 hours after multiple-dose administration of 1 mg tablets, and for 72 hours after multiple-dose administration of 1.25 mg/48 h patch. Compared with rasagiline tablets, the transdermal patch had a prolonged duration of 80% inhibition and increased maximal inhibition of MAO-B activity. These characteristics permitted an interval of 3 days of dosing, which was convenient for patients to use.
引用
收藏
页码:602 / 609
页数:8
相关论文
共 50 条
  • [21] Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects
    Jiao, Hui-Wen
    Sun, Lu-Ning
    Li, Yue-Qi
    Yu, Lei
    Zhang, Hong-Wen
    Wang, Mei-Feng
    Yu, Li-Yuan
    Yuan, Zi-Qing-Yun
    Xie, Li-Jun
    Chen, Juan
    Meng, Ling
    Zhang, Xue-Hui
    Wang, Yong-Qing
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (03) : 257 - 265
  • [22] Safety, pharmacokinetics, and pharmacodynamics of S-(−)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects
    Hui-Wen Jiao
    Lu-Ning Sun
    Yue-Qi Li
    Lei Yu
    Hong-Wen Zhang
    Mei-Feng Wang
    Li-Yuan Yu
    Zi-Qing-Yun Yuan
    Li-Jun Xie
    Juan Chen
    Ling Meng
    Xue-Hui Zhang
    Yong-Qing Wang
    European Journal of Clinical Pharmacology, 2018, 74 : 257 - 265
  • [23] Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers
    Kim, Yo Han
    Choi, Hee Youn
    Lim, Hyeong-Seok
    Lee, Shi Hyang
    Jeon, Hae Sun
    Hong, Donghyun
    Kim, Seong Su
    Choi, Young Kweon
    Bae, Kyun-Seop
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1419 - 1426
  • [24] Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
    Cawello, Willi
    Kim, Seong R.
    Braun, Marina
    Elshoff, Jan-Peer
    Ikeda, Junji
    Funaki, Tomoo
    CLINICAL DRUG INVESTIGATION, 2014, 34 (02) : 95 - 105
  • [25] Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects
    Patat, Alain
    Parks, Virginia
    Raje, Sangeeta
    Plotka, Anna
    Chassard, Didier
    Le Coz, F.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (03) : 299 - 308
  • [26] Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending single doses of SRA-333 in healthy subjects
    Plotka, A
    Parks, V
    Raje, S
    Patat, A
    Chassard, D
    NEUROBIOLOGY OF AGING, 2004, 25 : S212 - S212
  • [27] Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects
    Matsuno, Kumi
    Kuroda, Shingo
    Tanaka, Shingo
    Nakamichi, Hiroyuki
    Kagawa, Tomoya
    Koumura, Emiko
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (05) : 607 - 614
  • [28] Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects.
    Marino, MR
    Langenbacher, KM
    Ford, NF
    Uderman, HD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII53 - PII53
  • [29] Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects
    Ino, Hiroko
    Doi, Yohei
    Liefaard, Lia
    Cookson, Louise
    Chen, Chao
    Itoh, Hiroshi
    Igarashi, Harue
    Nakano, Atsushi
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05): : 612 - 618
  • [30] Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
    Willi Cawello
    Seong R. Kim
    Marina Braun
    Jan-Peer Elshoff
    Junji Ikeda
    Tomoo Funaki
    Clinical Drug Investigation, 2014, 34 : 95 - 105